SLC66A1

Across TCGA pan-cancer cohorts, SLC66A1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC66A1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SLC66A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC66A1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

OV, UCEC, and COAD are the cancer types where SLC66A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.160	0.541	.003	18	view →
UCEC	DFS	Median	All	1.000	0.631	.045	2	view →
COAD	DFS	Median	All	1.000	0.506	.047	1	view →
SKCM	DFS	Median	II,III,IV	0.736	0.217	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC66A1–OV (DFS)

Open the OV breakdown →